跳至主要内容
临床试验/NCT06886711
NCT06886711尚未招募不适用

A Study on the Safety and Efectiveness of Bifidobacterium Bifidum BBi32 in Improving Lntestinal and Lmmune Functions

Wecare Probiotics Co., Ltd.1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2025年3月10日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
45
试验地点
1
主要终点
Change in Fecal Microbiota Composition Before and After Intervention

研究概览

简要总结

Evaluate the efectiveness and safety of Bifidobacterium bifidum BBi32 as a food supplement compared to a placebo in improving intestinal andimmune functions in healthy adults.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Willing to attend 3 follow-up visits during the intervention period
  • Agree to provide blood, urine, and stool samples twice during the intervention period
  • Good eyesight, able to read and write, and capable of wearing glasses if needed
  • Good hearing and able to fully comprehend all instructions during the intervention

排除标准

  • Presence of digestive diseases, particularly gastrointestinal disorders (e.g., celiac disease, ulcerative colitis, Crohn's disease)
  • History of serious neurological conditions (e.g., epilepsy, stroke, severe head trauma, meningitis within the last 10 years, brain surgery, brain tumor, or prolonged coma-not including general anesthesia)
  • History of or currently receiving treatment for mental health disorders such as alcohol/drug/substance abuse, schizophrenia, psychosis, or bipolar disorder
  • Currently taking medication for depression or low mood
  • Presence of internal organ failure (e.g., heart, liver, or kidney failure)
  • History of radiation therapy or chemotherapy treatments
  • Underwent general anesthesia within the past three years or are scheduled for general anesthesia within the next 3 months during the trial period
  • History of hepatitis (B or C), HIV, or syphilis

结局指标

主要结局

Change in Fecal Microbiota Composition Before and After Intervention

时间窗: Baseline (Week 0) and post-intervention (Week 8)

Fecal microbiota composition will be analyzed using 16S rRNA gene sequencing to assess taxonomic and relative abundance changes.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验